The daily dose of testosterone-replacement therapy dependence from the body mass index in FtM transgender PATIENTS

L. Y. Sergeeva, A. Babenko
{"title":"The daily dose of testosterone-replacement therapy dependence from the body mass index in FtM transgender PATIENTS","authors":"L. Y. Sergeeva, A. Babenko","doi":"10.14341/probl12829","DOIUrl":null,"url":null,"abstract":"BACKGROUND BACKGROUND: The basis for the management of transgender patients is the use of various hormonal correction schemes necessary for changing the hormonal sex and, possibly, further preparation for surgical correction. Currently, the choice of the starting dose and the scheme is carried out empirically, which lengthens the period of selection of therapy and increases the risk of its complications. Taking into account the individual characteristics of the patient can help in optimizing therapy. AIM AIM: Investigate Factors Affecting the Daily Demand for Testosterone Ester Blends in Transgender Men MATERIALS AND METHODS MATERIALS AND METHODS: This study is a case-control observational study. Patients included prior to initiation of testosterone replacement therapy. The analysis of factors interrelated with the daily requirement of testosterone preparations was carried out. Among the factors of interest, the body mass index (BMI), the results of blood tests for total testosterone and the functional state of the liver and kidneys are considered. Testosterone replacement therapy (TRT) regimens were evaluated in transgender men. For the calculation, we used the formulas for BMI and the average daily dose of testosterone. Based on the data obtained, conclusions were drawn that allow determining the necessary TRT scheme in different trans-gender men at an early stage of hormonal correction. RESULTS RESULTS: Our study included 58 transgender FtM patients who were prescribed testosterone preparations with an identical composition. We found a positive correlation between BMI and testosterone dose in patients of group II (p = 0.04). CONCLUSION CONCLUSION: In the conclusion, the obtained schemes of hormonal sex reassignment with a minimum risk of possible complications are presented. Our results demonstrated a relationship between BMI in overweight and obese patients and the need for TRT. For patients with a BMI of 25 to 29 kg / m2, the interval between injections of a mixture of testosterone esters does not differ significantly from that in the group with a BMI below 25 kg / m2 and averages once every 18 days, and in the group with a BMI ≥ 30 kg / m2 tested testosterone ester preparations should be prescribed once every 2 weeks (14 days).","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"86 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problems of Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/probl12829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

BACKGROUND BACKGROUND: The basis for the management of transgender patients is the use of various hormonal correction schemes necessary for changing the hormonal sex and, possibly, further preparation for surgical correction. Currently, the choice of the starting dose and the scheme is carried out empirically, which lengthens the period of selection of therapy and increases the risk of its complications. Taking into account the individual characteristics of the patient can help in optimizing therapy. AIM AIM: Investigate Factors Affecting the Daily Demand for Testosterone Ester Blends in Transgender Men MATERIALS AND METHODS MATERIALS AND METHODS: This study is a case-control observational study. Patients included prior to initiation of testosterone replacement therapy. The analysis of factors interrelated with the daily requirement of testosterone preparations was carried out. Among the factors of interest, the body mass index (BMI), the results of blood tests for total testosterone and the functional state of the liver and kidneys are considered. Testosterone replacement therapy (TRT) regimens were evaluated in transgender men. For the calculation, we used the formulas for BMI and the average daily dose of testosterone. Based on the data obtained, conclusions were drawn that allow determining the necessary TRT scheme in different trans-gender men at an early stage of hormonal correction. RESULTS RESULTS: Our study included 58 transgender FtM patients who were prescribed testosterone preparations with an identical composition. We found a positive correlation between BMI and testosterone dose in patients of group II (p = 0.04). CONCLUSION CONCLUSION: In the conclusion, the obtained schemes of hormonal sex reassignment with a minimum risk of possible complications are presented. Our results demonstrated a relationship between BMI in overweight and obese patients and the need for TRT. For patients with a BMI of 25 to 29 kg / m2, the interval between injections of a mixture of testosterone esters does not differ significantly from that in the group with a BMI below 25 kg / m2 and averages once every 18 days, and in the group with a BMI ≥ 30 kg / m2 tested testosterone ester preparations should be prescribed once every 2 weeks (14 days).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FtM跨性别患者的体重指数对睾酮替代治疗日剂量的依赖性
背景:跨性别患者管理的基础是使用各种必要的激素矫正方案来改变激素性别,并可能为手术矫正做进一步的准备。目前,起始剂量和方案的选择都是经验性的,这延长了治疗的选择周期,增加了其并发症的风险。考虑到患者的个体特征可以帮助优化治疗。目的:探讨影响跨性别男性睾酮酯混合物日需求量的因素材料与方法材料与方法:本研究为病例对照观察性研究。包括开始睾酮替代治疗前的患者。对影响睾酮制剂日需要量的相关因素进行分析。在感兴趣的因素中,身体质量指数(BMI)、总睾酮的血液测试结果以及肝脏和肾脏的功能状态都被考虑在内。对跨性别男性进行睾酮替代疗法(TRT)方案评估。为了计算,我们使用了BMI和平均每日睾酮剂量的公式。根据所获得的数据,得出结论,可以确定不同跨性别男性在激素纠正早期所需的TRT方案。结果:我们的研究纳入了58名跨性别FtM患者,他们使用了相同成分的睾酮制剂。我们发现II组患者BMI与睾酮剂量呈正相关(p = 0.04)。结论:本研究提供了并发症风险最小的激素变性手术方案。我们的研究结果证明了超重和肥胖患者的BMI与TRT需求之间的关系。BMI为25 ~ 29 kg / m2的患者注射睾酮酯混合物的间隔时间与BMI低于25 kg / m2的患者注射睾酮酯混合物的间隔时间无显著差异,平均每18天注射一次,BMI≥30 kg / m2的患者每2周(14天)注射一次睾酮酯制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Resolution of the national interdisciplinary council of experts "High-dose vitamin D (Devilam) in the practice of an obstetrician-gynecologist" The daily dose of testosterone-replacement therapy dependence from the body mass index in FtM transgender PATIENTS Взаимодействие микробиома кишечника и пероральных сахароснижающих препаратов: обзор литератур Качество жизни пациентов с первичным гиперпаратиреозом после хирургического лечения The first experience of laser spectroscopy in the surgical treatment of thyroid diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1